Abstract Background Chronic myeloid leukemia (CML) has a low incidence but a high burden of disease, and is treated with high-cost tyrosine kinase inhibitors (TKI). Objective To determine the time from the start of a firstline TKI until it passes to sec
Usar patrones de inhibidores de tirosina cinasa de primera línea y tiempo para cambiar a terapia de segunda línea en leucemia mieloide crónica
Audifarma |
| Tiempo de lectura: Min
- Tema: Farmacoepidemiología
- Autores: Machado-Alba JE, Machado-Duque M.
- Idiomas: Inglés
- Palabras clave: BCR-ABL Positive Chronic Leukemia Myelogenous Pharmacoepidemiology Treatment failure
Machado-Alba, J. E., Machado-Duque, M. E. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia. International journal of clinical pharmacy.2017;39(4): 851-859. Enlace: https://link.springer.com/article/10.1007%2Fs11096-017-0484-9
